#Photocure
LightNews LightNews
darkcap1.bsky.social
Litt spennende i $pho mfn.se/ob/a/photocu...
Photocure ASA - Major shareholding disclosure
On 28 February 2025, Briarwood Chase Management LLC, via a private investment fund under its management, bought 370,000 shares in Photocure ASA. Following this, Briarwood Chase Management LLC contr...
mfn.se
February 28, 2025 at 2:54 PM
newsen.bsky.social
Photocure and Artera Collaborate on Digital Pathology AI for Bladder Cancer Evaluation#Norway#Oslo#Bladder_Cancer#Photocure#Artera
Photocure and Artera Collaborate on Digital Pathology AI for Bladder Cancer Evaluation
A new collaboration between Photocure and Artera aims to enhance bladder cancer diagnostics through AI-powered pathology tests, supporting precision medicine.
third-news.com
June 8, 2026 at 5:47 PM
newsen.bsky.social
Photocure ASA Reports Strong Growth for First Quarter of 2026#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure ASA Reports Strong Growth for First Quarter of 2026
Photocure ASA announced impressive revenue growth in Q1 2026, driven by product expansion and strategic initiatives in bladder cancer management.
third-news.com
May 7, 2026 at 9:18 AM
newsen.bsky.social
Photocure ASA Reports Strong First Quarter Performance for 2026#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure ASA Reports Strong First Quarter Performance for 2026
Photocure ASA achieved impressive revenue growth in Q1 2026 driven by enhanced adoption of its innovative cancer detection technologies, reflecting strong operational execution across markets.
third-news.com
May 7, 2026 at 6:17 AM
newsen.bsky.social
Photocure and Artera Forge Partnership to Enhance Bladder Cancer Diagnostics Using AI Technologies#Norway#Oslo#Bladder_Cancer#Photocure_ASA#Artera
Photocure and Artera Forge Partnership to Enhance Bladder Cancer Diagnostics Using AI Technologies
Photocure and Artera announce a partnership focused on improving bladder cancer diagnostics with AI, promising personalized patient care and advanced detection methods.
third-news.com
June 8, 2026 at 5:36 PM
newsen.bsky.social
Photocure ASA Reports Strong Q1 2026 Results with Growth in Revenues and Strategic Advancements#Norway#Oslo#Photocure_ASA#Hexvix#BLC_Technology
Photocure ASA Reports Strong Q1 2026 Results with Growth in Revenues and Strategic Advancements
Photocure ASA unveiled impressive Q1 2026 results, with significant revenue growth driven by strategic expansions in blue-light cystoscopy and regulatory advancements, signaling a strong future.
third-news.com
May 7, 2026 at 6:28 AM
newsen.bsky.social
New Health Economic Approach Analyzes Cost-Effectiveness of BLC vs NBI in Bladder Cancer Diagnostics#Norway#Oslo#Bladder_Cancer#Photocure#health_economics
New Health Economic Approach Analyzes Cost-Effectiveness of BLC vs NBI in Bladder Cancer Diagnostics
Photocure ASA recently unveiled a study comparing the cost-effectiveness of Blue Light Cystoscopy with Narrow Band Imaging for bladder cancer, revealing significant findings for healthcare appraisal.
third-news.com
May 4, 2026 at 6:36 AM
xtrainvestor.bsky.social
Ny episode av AksjeSladder: Heksesalg, Innsidepusher og Marshåp
Innhold: 01:28 Siste ukers handler. 24:32 Emisjoner og nedsalg. 31:50 Selger Euronext innsideinformasjon?
soundcloud.com/user-3682964...
Heksesalg, Innsidepusher og Marshåp
Innhold: 01:28 Siste ukers handler med bl.a. Argeo, Ultimovacs, Smartcraft, ABG, Photocure, Horisont Energi, Arctic Bioscience, Subsea 7, EAM, SD Standard ETC, Hafnia m fl. 24:32 Emisjoner og nedsalg
soundcloud.com
March 1, 2025 at 9:34 AM
newsen.bsky.social
Study Shows Blue Light Cystoscopy Enhances Management of High-Risk NMIBC in AUA 2026#USA#Washington_D.C.#NMIBC#Photocure#BLC
Study Shows Blue Light Cystoscopy Enhances Management of High-Risk NMIBC in AUA 2026
Recent research presented at AUA 2026 reveals how Blue Light Cystoscopy enhances early detection and management of high-risk NMIBC, influencing treatment decisions and costs.
third-news.com
May 18, 2026 at 3:47 PM
newsen.bsky.social
AUA 2026: The Impact of Blue Light Cystoscopy on High-Risk NMIBC Patient Management#USA#Washington_DC#Bladder_Cancer#Blue_Light#Photocure
AUA 2026: The Impact of Blue Light Cystoscopy on High-Risk NMIBC Patient Management
The 2026 AUA congress unveiled new studies showcasing the advantages of Blue Light Cystoscopy in managing high-risk non-muscle invasive bladder cancer (NMIBC), emphasizing cost-effectiveness.
third-news.com
May 18, 2026 at 3:47 PM
newsen.bsky.social
Asieris Receives Approval for CEVIRA as the First Non-Invasive Therapy for Cervical Precancerous Lesions in China#China#N/A#Photocure#CEVIRA#Asieris
Asieris Receives Approval for CEVIRA as the First Non-Invasive Therapy for Cervical Precancerous Lesions in China
Asieris Pharmaceuticals has achieved a significant milestone with the approval of CEVIRA in China, marking the first non-invasive therapy for cervical precancerous lesions.
third-news.com
March 3, 2026 at 10:10 AM
jobboardsearch.com
📢 Photocure is #hiring a Marketing Director, Biomarkers!

🌎 Worldwide

🔗 http://jbs.ink/bLRKyCrYDXMN

#jobalert #jobsearch #aviationjobs #remotejob #remotework #wfh #marketing #finance
📢 Photocure is hiring a Marketing Director, Biomarkers!
September 6, 2026 at 9:07 PM
aihealth-hub.bsky.social
Bladder cancer care has long suffered from a lack of reliable biomarkers. A new partnership between Photocure and Artera aims to train AI on clinical registry data to predict tumor behavior. Can AI solve a diagnostic gap where genomics stalled?
AI Tackles the Bladder Cancer Biomarker Deficit
A new partnership aims to bring precision medicine to a disease long starved of reliable biomarkers.
yesilscience.com
August 17, 2026 at 5:01 AM
openbionews.com
Three biopharma items survived a politically noisy Saturday: an FDA reclassification proposal for Photocure's cystoscopy franchise, a successful USFDA inspection at Aurisco, and an op-ed on AI terminology in pharma.
https://openbionews.com/analysis/daily-bio-news-summary-2026-08-16/
Daily Bio News Summary — 2026-08-16: Three biopharma items survive a politically noisy Saturday | Data Analysis | OpenBio News
After filtering, only 3 biopharma-relevant items made the cut on 2026-08-16: an FDA reclassification proposal that affects Photocure
openbionews.com
August 17, 2026 at 2:09 AM
newsen.bsky.social
Photocure Applauds FDA's Move to Reclassify Blue Light Cystoscopy Systems, Enabling Broader Access#USA#FDA#Oslo#Photocure#Cysview
Photocure Applauds FDA's Move to Reclassify Blue Light Cystoscopy Systems, Enabling Broader Access
Photocure welcomed the FDA's proposal to reclassify blue light cystoscopy systems, potentially enhancing bladder cancer detection and patient access in the U.S.
third-news.com
August 14, 2026 at 4:27 PM
l2plabs.bsky.social
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II
OSLO, Norway, Aug. 14, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced that the U.S. Food and Drug Administration (FDA) has published a proposed order in the Federal Register to initiate the process of reclassifying cystoscopic systems intended...
dlvr.it
August 14, 2026 at 4:27 PM
l2plabs.bsky.social
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II
OSLO, Norway, Aug. 14, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced that the U.S. Food and Drug Administration (FDA) has published a proposed order in the Federal Register to initiate the process of reclassifying cystoscopic systems intended...
dlvr.it
August 14, 2026 at 4:22 PM
newsen.bsky.social
FDA Proposes Reclassification of Blue Light Cystoscopy Devices to Enhance Bladder Cancer Detection#USA#Oslo#Photocure#Cystoscopy#BLC
FDA Proposes Reclassification of Blue Light Cystoscopy Devices to Enhance Bladder Cancer Detection
The FDA has proposed a reclassification of blue light cystoscopy systems, a significant step to improve bladder cancer detection in the U.S.
third-news.com
August 14, 2026 at 4:28 PM
l2plabs.bsky.social
Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S.
OSLO, Norway, August 11, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective...
dlvr.it
August 11, 2026 at 6:54 AM
newsen.bsky.social
New OPTUM Study Confirms Cost Neutrality of BLC Compared to WLC for Bladder Cancer Diagnosis#USA#Oslo#Photocure#BLC#WLC
New OPTUM Study Confirms Cost Neutrality of BLC Compared to WLC for Bladder Cancer Diagnosis
A recent OPTUM study illustrates the cost-neutral impact of blue light versus white light cystoscopy for diagnosing non-muscle-invasive bladder cancer, highlighting significant clinical advantages.
third-news.com
August 11, 2026 at 7:04 AM
newsen.bsky.social
Photocure ASA Reports Second Quarter 2026 Financial Results and Strategic Progress#Norway#Oslo#Bladder_Cancer#Photocure_ASA#Hexvix_Cysview
Photocure ASA Reports Second Quarter 2026 Financial Results and Strategic Progress
Photocure ASA has announced its financial outcomes for Q2 2026, highlighting growth in Hexvix®/Cysview® revenues and strategic milestones in bladder cancer diagnostics.
third-news.com
July 29, 2026 at 6:43 AM
newsen.bsky.social
Photocure ASA Reports Strong Revenue Growth for Q2 2026 with Exciting Future Prospects#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure ASA Reports Strong Revenue Growth for Q2 2026 with Exciting Future Prospects
In its Q2 2026 financial report, Photocure ASA revealed impressive growth in revenues and advancements in bladder cancer diagnostics, with exciting future plans.
third-news.com
July 29, 2026 at 6:30 AM
babygoldie.bsky.social
[1/3] 2026-07-23 17:13:19 - [Yahong Pharmaceutical: Sued due to contract dispute, involving US$4.4 million and related expenses] Yahong Pharmaceutical announced that it recently received an arbitration application from the American Arbitration Association. The applicant Photocure
July 23, 2026 at 9:35 AM